Over the last few decades, the pharmaceutical industry has been using batch processes for production of pharmaceutical products, which is a multi-phase process. However, the surge in the demand for drugs due to COVID-19 has led the pharmaceutical industry to shift on to a more agile and flexible technique- continuous, which is a single flow process allowing the industry to scale up quick, manufacture easily and shortens the drug supply chain. In fact, the USFDA has categorized continuous as one of today’s most important tools for modernizing the pharmaceutical industry.
Moreover, the continuous processes use advanced sensors, and in-process analytics that enable the measurement of critical parameters and processing conditions in real-time.
Highlights on comparison of batch manufacturing Technique and Continuous Manufacturing Technique
Batch manufacturing technique
Continuous manufacturing technique
Cost of production
Relatively a slower process; increases the cost of production
Comparatively a faster process; reduces the cost of production
Requires shutting down of the whole equipment on a regular interval; makes the process, time consuming
Does not require shutting down the equipment; time-efficient process
High energy consumption while starting the equipment
Lesser energy consumption being a continuous process
Requires multiple human operators for the production of each batch; the risk of human errors is significantly high
Requires much less human attention; reduced human errors
Monitoring of batch is only possible after the completion of process
Monitoring is possible due to PAT and closed-loop automated process
Batch / lot generation
Specific number of batches are generated at a time
Batches are generated as per the demand
Larger floor-space required
Lesser floor-space required
High risk of batch-to-batch inconsistencies
Low risk of batch-to-batch inconsistencies
List of Companies Offering Continuous Manufacturing
Currently, over 70 companies across the globe claim to offer continuous manufacturing services. Over 90% of the companies are engaged in offering services for API manufacturing, while only 53% of the companies offer the services related to final dosage form. Furthermore, it is interesting to note that 49% of the continuous manufacturing players are predominantly present in Europe.
There has been a significant increase in the number of expansions in order to adopt continuous manufacturing since 2016. Majority of expansions were signed in the Europe (primarily in Germany and United Kingdom). Moreover, close to 50% instances were related to plant establishment followed by technology enhancement (30%).
Adoption of Continuous Manufacturing
As per the interviews conducted with industry stakeholders, the industry is currently in the initial stages of adopting continuous manufacturing. However, the ongoing COVID-19 crisis is likely to accelerate the industry’s shift to these systems. In fact, a number of established big pharma players have already adopted these systems.
Keeping every trend in mind, Roots Analysis has provided complete information on market trends in continuous manufacturing domain, which has some of the very recent and precise activities listed for the clients to help them make better decisions in its upcoming report titled, Continuous Manufacturing (Small Molecule and Biologics) Market, 2nd Edition, 2022-2035. To find answers to key decision-making question and to know further about the market forecast analysis, highlighting the likely growth of the Continuous Manufacturing (Small Molecule and Biologics) Market, for the time period 2022-2035.
For more details on this emerging domain, check out the following report: